Long non‑coding RNA B4GALT1‑Antisense RNA&nbsp;1/microRNA‑30e/SRY‑box transcription factor&nbsp;9 signaling axis contributes to non‑small cell lung cancer cell growth

Lin,Jie-Huan; Chen,Fu-Nan; Wu,Can-Xing; Hu,Shu-Qiao; Ma,Jun

doi:10.3892/ol.2020.12146

Long non‑coding RNA B4GALT1‑Antisense RNA 1/microRNA‑30e/SRY‑box transcription factor 9 signaling axis contributes to non‑small cell lung cancer cell growth

Authors:
- Jie-Huan Lin
- Fu-Nan Chen
- Can-Xing Wu
- Shu-Qiao Hu
- Jun Ma
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, The First Hospital of Longyan City, Longyan, Fujian 364000, P.R. China
Published online on: September 23, 2020 https://doi.org/10.3892/ol.2020.12146
Article Number: 284
Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding (lnc) RNAs serve crucial functions in human cancers. However, the involvement of the lncRNA B4GALT1‑antisense RNA 1 (AS1) in non‑small cell lung cancer (NSCLC) has not been extensively studied. Reverse transcription‑quantitative PCR was performed to detect B4GALT1‑AS1 levels in NSCLC tissues and cell lines. Potential influences of B4GALT1‑AS1 on biological functions of NSCLC were assessed through a series of in vitro experiments, and the molecular mechanism was determined via RNA immunoprecipitation (RIP) and bioinformatics analyses. The results of the present study demonstrated that knockdown of B4GALT1‑AS1 significantly attenuated the proliferative ability and clonality of H1299 and A549 cells. In the present study, B4GALT1‑AS1 competed as an endogenous RNA by sequestering microRNA‑30e (miR‑30e) leading to an enhanced expression of SRY‑box transcription factor 9 (SOX9). The effects of silencing B4GALT1‑AS1 on NSCLC cells proliferation could be ameliorated by inhibiting miR‑30e or restoring SOX9. Hence, B4GALT1‑AS1 acted as a lncRNA that drives tumor progression in NSCLC via the regulation of the miR‑30e/SOX9 axis. The findings of the present study indicated that the B4GALT1‑AS1/miR‑30e/SOX9 axis maybe an effective target for NSCLC treatment and management.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI
2	Zhao J, Mao Z, Fedewa SA, Nogueira L, Yabroff KR, Jemal A and Han X: The affordable care act and access to care across the cancer control continuum: A review at 10 years. CA Cancer J Clin. 70:165–181. 2020.PubMed/NCBI
3	Noone AM, Cronin KA, Altekruse SF, Howlader N, Lewis DR, Petkov VI and Penberthy L: Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992–2013. Cancer Epidemiol Biomarkers Prev. 26:632–641. 2017.PubMed/NCBI
4	Singh M and Jadhav HR: Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. Drug Discov Today. 23:745–753. 2018.PubMed/NCBI
5	Hill A, Gupta R, Zhao D, Vankina R, Amanam I and Salgia R: Targeted therapies in non-small-cell lung cancer. Cancer Treat Res. 178:3–43. 2019.PubMed/NCBI
6	Batista PJ and Chang HY: Long noncoding RNAs: Cellular address codes in development and disease. Cell. 152:1298–1307. 2013.PubMed/NCBI
7	Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell. 136:629–641. 2009.PubMed/NCBI
8	Hauptman N and Glavac D: Long non-coding RNA in cancer. Int J Mol Sci. 14:4655–4669. 2013.PubMed/NCBI
9	Bao Z, Yang Z, Huang Z, Zhou Y, Cui Q and Dong D: lncRNADisease 2.0: An updated database of long non-coding RNA-associated diseases. Nucleic Acids Res. 47:D1034–D1037. 2019.PubMed/NCBI
10	Han S, Cao D, Sha J, Zhu X and Chen D: lncRNA ZFPM2-AS1 promotes lung adenocarcinoma progression by interacting with UPF1 to destabilize ZFPM2. Mol Oncol. 14:1074–1088. 2020.PubMed/NCBI
11	Yang S, Liu T, Sun Y and Liang X: The long noncoding RNA LINC00483 promotes lung adenocarcinoma progression by sponging miR-204-3p. Cell Mol Biol Lett. 24:702019.PubMed/NCBI
12	Zhao M, Xin XF, Zhang JY, Dai W, Lv TF and Song Y: lncRNA GMDS-AS1 inhibits lung adenocarcinoma development by regulating miR-96-5p/CYLD signaling. Cancer Med. 9:1196–1208. 2020.PubMed/NCBI
13	Han L, Kong R, Yin DD, Zhang EB, Xu TP, De W and Shu YQ: Low expression of long noncoding RNA GAS6-AS1 predicts a poor prognosis in patients with NSCLC. Med Oncol. 30:6942013.PubMed/NCBI
14	Luo Z, Han Z, Shou F, Li Y and Chen Y: LINC00958 accelerates cell proliferation and migration in non-small cell lung cancer through JNK/c-JUN signaling. Hum Gene Ther Methods. 30:226–234. 2019.PubMed/NCBI
15	Zhang Y, Fang Z, Guo X, Dong H, Zhou K, Huang Z and Xiao Z: lncRNA B4GALT1-AS1 promotes colon cancer cell stemness and migration by recruiting YAP to the nucleus and enhancing YAP transcriptional activity. J Cell Physiol. 234:18524–18534. 2019.PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI
17	Liu C, Yang Z, Deng Z, Zhou Y, Gong Q, Zhao R and Chen T: Downregulated miR-30e contributes to progression of lung adenocarcinoma through elevating the expression of SOX9. Cancer Med. 7:5554–5566. 2018.PubMed/NCBI
18	Chu F, Xue L and Miao H: Long noncoding RNA TP73-AS1 in human cancers. Clin Chim Acta. 500:104–108. 2020.PubMed/NCBI
19	Gourvest M, Brousset P and Bousquet M: Long noncoding RNAs in acute myeloid leukemia: Functional characterization and clinical relevance. Cancers (Basel). 11:16382019.
20	Lu T, Wang Y, Chen D, Liu J and Jiao W: Potential clinical application of lncRNAs in non-small cell lung cancer. Onco Targets Ther. 11:8045–8052. 2018.PubMed/NCBI
21	Abdollahzadeh R, Daraei A, Mansoori Y, Sepahvand M, Amoli MM and Tavakkoly-Bazzaz J: Competing endogenous RNA (ceRNA) cross talk and language in ceRNA regulatory networks: A new look at hallmarks of breast cancer. J Cell Physiol. 234:10080–10100. 2019.PubMed/NCBI
22	Wang X, Ju Y, Zhou MI, Liu X and Zhou C: Upregulation of SOX9 promotes cell proliferation, migration and invasion in lung adenocarcinoma. Oncol Lett. 10:990–994. 2015.PubMed/NCBI
23	Wang X, Liu Y, Liu X, Yang J, Teng G, Zhang L and Zhou C: miR-124 inhibits cell proliferation, migration and invasion by directly targeting SOX9 in lung adenocarcinoma. Oncol Rep. 35:3115–3121. 2016.PubMed/NCBI
24	Zhang YJ, Xu F, Zhang YJ, Li HB, Han JC and Li L: miR-206 inhibits non small cell lung cancer cell proliferation and invasion by targeting SOX9. Int J Clin Exp Med. 8:9107–9113. 2015.PubMed/NCBI
25	miR-32 functions as a tumor suppressor and directly targets SOX9 in human non-small cell lung cancer [Retraction]. Onco Targets Ther. 9:63792016.PubMed/NCBI